Literature DB >> 7780657

Further investigations into adenosine A1 receptor-mediated contraction in rat colonic muscularis mucosae and its augmentation by certain alkylxanthine antagonists.

J J Reeves1, J E Jarvis, M J Sheehan, P Strong.   

Abstract

1. The alkylxanthine antagonists, 8-phenyltheophylline (8-PT), 8-p-sulphophenyltheophylline (8-SPT) and 1,3,7-trimethylxanthine (caffeine) produced rightward displacements of contractile concentration-effect curves to 5'-N-ethylcarboxamidoadenosine (NECA) in rat isolated colonic muscularis mucosae (RCMM) with concentration-ratios consistent with adenosine receptor blockade. The non-xanthine antagonist, 9 fluro-2-(2-furyl)-5,6-dihydro [1,2,4] triazo to [1,5-c]-quinazin-imine (CGS15943A) also antagonized contractions to NECA with an affinity (pKB8.1-8.5) consistent with adenosine A1 receptor blockade. 2. In addition to producing rightward shifts of the concentration-response curves, the maximum contractions to 5'-N-ethylcarboxamidoadenosine (NECA) were also markedly increased in the presence of 8-PT (by 83 +/- 16% at 1 microM), 8-SPT (by 37 +/- 7% at 10 microM) and caffeine (by 45 +/- 5% at 100 microM) but were unaffected by CGS15943A (at 0.01 and 0.03 microM). 3. As with NECA, the maximum contractions to the adenosine A1 receptor agonists R-phenylisopropyladenosine (R-PIA) and N-[(1S, trans)-2-hydroxyclopentyl] adenosine (GR79236) were both antagonized and augmented by 8-PT. In addition, the contractions to NECA in the presence of 8-PT (1 microM) were inhibited by nanomolar concentrations of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). 4. The non-selective phosphodiesterase (PDE) inhibitor, 3-isobutyl-1-methylxanthine (1 microM) produced a marked increase in the NECA maximum without producing a rightward shift in the NECA curve, whereas a higher concentration (10 microM) virtually abolished responses. The PDE type III inhibitor,milrinone (1 microM), the type IV inhibitor, rolipram (10 microM), and the type V PDE inhibitor, zaprinast(3 microM), were all without effect on NECA responses in RCMM.5. Partial inhibitions of contractions to NECA were produced by indomethacin (at 3 or 10 micro M) or piroxicam (at 3 microM). Responses to GR79236 were also partially inhibited by indomethacin. In the presence of indomethacin, 8-PT was still able to enhance markedly the maximum contractions obtained to NECA in RCMM.6. The present study has shown that certain alkylxanthine antagonists (but not the non-xanthineCGS15943A) produced a marked augmentation of adenosine Al receptor-mediated contractions inRCMM. The mechanism of this augmentation is, as yet, not known but is unlikely to result from inhibition of PDE. This study has also shown that adenosine Al receptor-induced contractions inRCMM are mediated, in part, via products of the cyclo-oxygenase pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780657      PMCID: PMC1510320          DOI: 10.1111/j.1476-5381.1995.tb13304.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity.

Authors:  F W Smellie; C W Davis; J W Daly; J N Wells
Journal:  Life Sci       Date:  1979-06-25       Impact factor: 5.037

Review 2.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

3.  PD 116,948, a highly selective A1 adenosine receptor antagonist.

Authors:  S J Haleen; R P Steffen; H W Hamilton
Journal:  Life Sci       Date:  1987-02-09       Impact factor: 5.037

4.  Characterisation of human adenosine type 1, 2a and 2b receptors expressed in CHO cells.

Authors:  P J Rollins; S J Turner; C I Akpoguma; K P Ray
Journal:  Biochem Soc Trans       Date:  1994-05       Impact factor: 5.407

5.  Comparison of the potency of 8-phenyltheophylline as an antagonist at A1 and A2 adenosine receptors in atria and aorta from the guinea-pig.

Authors:  M G Collis; D B Palmer; V L Saville
Journal:  J Pharm Pharmacol       Date:  1985-04       Impact factor: 3.765

6.  Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist.

Authors:  G Ghai; J E Francis; M Williams; R A Dotson; M F Hopkins; D T Cote; F R Goodman; M B Zimmerman
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

7.  Action of adenosine in estrogen-primed nonpregnant guinea pig myometrium: characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism.

Authors:  W P Schiemann; K O Doggwiler; I L Buxton
Journal:  J Pharmacol Exp Ther       Date:  1991-08       Impact factor: 4.030

8.  Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist.

Authors:  M Williams; J Francis; G Ghai; A Braunwalder; S Psychoyos; G A Stone; W D Cash
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

9.  Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes.

Authors:  R F Bruns; J H Fergus; E W Badger; J A Bristol; L A Santay; J D Hartman; S J Hays; C C Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-01       Impact factor: 3.000

10.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.

Authors:  A J Hutchison; R L Webb; H H Oei; G R Ghai; M B Zimmerman; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

View more
  1 in total

Review 1.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.